(Country; Symbol)


Type Of Agreement

Product Area

Details (Date)

Aclara BioSciences Inc. (ACLA) Laboratory

Lawrence Livermore National

Service and supply agreement

To provide access to Aclara's eTag Assay System to develop rapid detection assays for biological agents

The agreement includes supply of eTag assay reagent products, software and services (4/8)

Aclara BioSciences Inc. (ACLA)

University of Southern California's Norris Comprehensive Cancer Center and Hospital


To identify and characterize clinical biomarkers for cancer

The parties will apply Aclara's multiplexed eTag Assay System to discover breast cancer biomarkers (4/16)

Adherex Technologies Inc. (Canada; TSE:AHX)

National Cancer Institute

Screening agreement

To evaluate the anti-cancer effects and vascular-targeting capabilities of compounds from Adherex's library of cadherin antagonists

The classes of agents to be included under the agreement include peptidecadherin antagonist compounds for N-cadherin, E-cadherin, desmogleins, VE-cadherin and OB-cadherin, as well as Adherex's non-peptide cadherin antagonists (5/13)

Advanced Biosystems Inc. (subsidiary of Analex Corp.; AMEX:NLX)

Defense Advanced Research Projects Agency


To develop capabilities and techniques for use in creating and evaluating surrogate lung tissues and their suitability as tools in the study of infection

The 10-month contract is worth about $2M for Advanced Biosystems (5/1)

A.I. Software Inc.* (Canada)

Technion University of Israel and the Weizmann Institute (Israel)

Licensing agreement

For a stem cell expansion technology

The company will develop a process to assist with bone marrow transplants (4/24)

Althea Technologies Inc.*

National Institutes of Health

Four-year contract

To assist the National Institute of Allergy and Infectious Diseases with the development, scaleup and production of candidate vaccines

The contract also calls for Althea to perform the necessary characterization tests required for release of vaccines for clinical use (4/15)

Applied Imaging Corp. (AICX)

Wellcome Trust Sanger Institute (UK)


For Applied Imaging to be sole imaging development partner in Sanger's Atlas of Gene Expression project

Applied Imaging will develop applications for high-throughput analysis of tissue samples using its Ariol software; Applied Imaging will have exclusive worldwide commercial rights to sell the various Ariol applications developed under the agreement (4/29)

Arius Research Inc. (Canada; VSE:YAR) models of human ovarian cancer

Ottawa Regional Cancer Centre (Canada)


To study a group of cancer-killing antibodies in specialized

ORCC will test the antibodies in its models for drug efficacy (5/1)

Astex Technology Ltd.*

Institute of Cancer Research Technology (UK)

Exclusive agreement enzyme protein

For the discovery of drugs against the and develop drug candidates for kinase B

Astex and the institute established a joint research team to identify (UK) indications in the oncology area (3/20)

Biosyn Inc.*

National Institutes of Health

Exclusive worldwide rights agreement

To develop and commercialize a protein called cyanovirin-N as an HIV microbicide

Further details were not disclosed (4/3)

BioVex Ltd.* (UK)

Vaccine Research Center at the National Institute of Allergy and Infectious Diseases


To develop an HIV vaccine using BioVex's ImmunoVEX herpes simplex-based platform

The vaccine would incorporate a combination of VRC's HIV antigen genes aimed at maximizing the immune response to the virus (5/12)

Carrington Laboratories Inc. (CARN)

Southern Research Institute


To develop a platform to improve sustained delivery of therapeutic proteins and peptides

The agreement is for five years (5/1)

Cellomics Inc.*

Mayo Clinic and Foundation


To provide access to Cellomics' range of products, including the Array-Scan HCS Reader, the KineticScan HCS Reader, the vHCS Discovery ToolBox and the line of Bio-Application software modules for automated cell analyses

Financial details were not disclosed (4/30)

CombiMatrix Corp. (CBMX)

Nihon Gene Research Laboratory (Japan)


To sell a DNA Micro-array Synthesizer

NGRL will supply the Japanese market with a custom microarray production and analysis service; the two parties also entered an agreement to investigate various aspects of genetic analysis (4/7)

Commonwealth Biotechnologies Inc. (CBTE)

National Institute of Justice

Purchase agreement

For performance of DNA genotyping work associated with convicted offenders

The agreement is for April 1, 2003, through March 31, 2004, and is valued at $25M (5/5)

Cyclacel Ltd.* (UK)

Cancer Research Technology Ltd. and the University of Cambridge (UK)


To develop RNA interference technology for target validation and drug discovery

The parties have combined intellectual property; collaboration is aimed at improving RNAi technology in mammalian cells to allow the generation of new disease models and systems for analyzing mammalian gene expression (3/31)

CytRx Corp.

University of Massachusetts Medical School

Licensing agreements

For a portfolio of applications for gene silencing technology in the areas of Type II diabetes, obesity and cancer

CytRx is giving up 1.6M shares in the agreement (4/21)

DelSite Biotechnologies Inc. (subsidiary of Carrington Laboratories Inc.; CARN)

University of Southern Mississippi of protein and peptide therapeutics


To develop water-soluble polymer technology for the controlled release

The program will operate under the direction of the school's department of polymer science (5/6)

DiaDexus Inc.*

Mayo Medical Laboratories


To provide analyte-specific reagents to Mayo

Mayo will use the reagents to develop a test for the quantitative measurement of lipoprotein-associated phospholipase A2 in blood (3/28)

Diversa Corp. (DVSA)

U.S. Department of Energy's Joint Genome Institute


To discover and sequence microbial genomes found in arange of habitats

Diversa will use its technologies to extract DNA from environmental samples and make gene libraries, while JGI will perform DNA sequencing (5/5)

Domantis Ltd.*

UK Medical Research Council (UK)


For exclusive access to a novel polymerase technology, which will accelerate the discovery of polypeptides, including the domain antibodies in which Domantis specializes

The aim is to create a “polymerase engine," enabling Domantis to select polypeptides with improved properties; the company also will license the technique to reagent and diagnostic companies that want to access new polymerases (4/16)

DOR BioPharma

Thomas Jefferson University

Exclusive worldwide license agreement

For an intellectual property portfolio related to development of vaccines to combat intoxication by botulinum toxin

More than $2.1M of grant support from the National Institutes of Health was invested in developing the vaccine candidates and related work on the mechanisms of botulinum toxin (5/7)

Elixir Pharmaceuticals Inc.*

National Human Genome Research Institute and University of Michigan


To study the relationship of the Lamin A gene to the normal the aging process

Further details were not disclosed (4/25)

Exact Sciences Corp. (EXAS)

Johns Hopkins Kimmel Cancer Center

Licensing agreement

For the cancer center's digital PCR technology

The technology could lead to the development of colorectal cancer screening and detection technologies that may enhance Exact Sciences' PreGen-Plus assay (4/24)

Genaissance Pharmaceuticals Inc. (GNSC)

Wayne State University


To support the university's research contract with the National Institute of Child Health and Human Development's Perinatology Research Branch

The university will gain access to specific HAP markers and receive a limited license to use Genaissance's DecoGen Informatics System; Genaissance will develop assays for the selected HAP markers and provide high-throughput genotyping on clinical samples; Genaissance will receive a license fee and other payments from the university (3/25)

Genedata AG* (Switzerland)

National Cancer Center (Japan)

Research collaboration

To identify minimal sets of diagnostic marker proteins decisive for delineating cancer types into subclasses

Genedata licensed its Impressionist product to the National Cancer Center, which will use it in conjunction with 2D-protein gel data derived from Ettan DIGE technology from Amersham Biosciences (5/12)

GenVec Inc.

National Institutes of Health


To develop a vaccine for severe acute respiratory syndrome (SARS)

The government will be in charge of testing the vaccine candidate in preclinical models to assess safety and efficacy, after which clinical trials may start (4/25)

Hemispherx Biopharma Inc. (AMEX:HEB)

Center for Cell and Gene Therapy at Baylor College of Medicine


For work conducted using the Phase III drug Ampligen in the implementation of the protocol titled “Administration of neomycin resistance gene-marked LMP2a-specific CTL to patients with relapsed EBV-positive Hodgkin's lymphoma"

Hemispherx will provide Ampligen and Baylor College will conduct and fund the research (5/5)

Hemispherx Biopharma Inc.(AMEX:HEB)

Genome Institute (Singapore)

Research collaboration

To test its lead products in treating severe acute respiratory syndrome (SARS)

Hemispherx plans to test its Alferon N product and Ampligen (5/13)

Iconix Pharmaceuticals Inc.*

University of California at Berkeley

Licensing agreement

For exclusive rights to data-mining tools for experiments in predictive chemo-genomics

Iconix will apply data-mining tools created by Laurent El Ghaoui of the university to develop additional drug signatures (4/23)

IGEN International Inc. (IGEN)

Food Safety and Inspection Service of the U.S. Department of Agriculture

Purchase agreement

For IGEN's botulinum toxin test

The service will use the test as part of an expansion of its Homeland Security program for food safety (4/21)

IGEN International Inc. (IGEN)

U.S. Air Force


For the detection of biological agents in order to protect military personnel

The products are based on IGEN's Origen technology and are able to detect select biological agents within 30 minutes (3/20)

Immucor Inc. (BLUD) and Bio-Tek Instruments Inc.*

University of Vermont


To commercialize an in vitro diagnostic test to measure platelet markers used in antiplatelet pharmacological drug development and to potentially improve real-time treatment of cardiovascular disease

The assay is expected to be used in determining the risk associated with increased platelet activity and decreased reactivity (4/30)

Ingenium Pharmaceuticals AG* (Germany)

Molecular Genetics Laboratory of the University Eye Hospital (Germany)


For Ingenium to use its INGENOtyping technology platform to develop animal models with defined gene alterations

The collaboration is focused on genes relating to eye diseases (4/16)

Ingenuity Systems Inc.*



To test existing chemotherapeutic agents against recently discovered gene defects associated with prostate and brain cancer pathways

Financial terms were not disclosed (4/1)

Introgen Therapeutics Inc. (INGN)

The University of Texas M.D. Anderson Cancer Center

Exclusive worldwide license agreement

For the fus1 gene

The gene is believed to inhibit the growth of tumors and reduce the spread of lung cancer in animals; Introgen gained rights to the gene (5/1)

LaunchCyte LLC*

University of Pittsburgh

Exclusive option agreement

For LaunchCyte to license a platelet non-adhesion technology

LaunchCyte will evaluate the technology while developing commercialization and funding strategies toward the creation of a new venture (4/10)

Technologies Inc.*


Cooperative research and development agreement

To develop data-mining tools to assess drug safety

Further details were not disclosed (5/2)

Lynx Therapeutics Inc. (LYNX)

Institute for Systems Biology

Service agreement

To study prostate cancer gene expression using Lynx's Massively Parallel Signature Sequencing technology

Lynx will receive payments for the genomics discovery services it performs on samples provided by the institute (5/14)

Lynx Therapeutics Inc. (LYNX)

National Institute on Aging

Service agreement

To study stem cell gene expression using Lynx's Massively Parallel Signature Sequencing technology

Lynx will receive payments for the genomics discovery services it performs on samples provided by the NIA (5/7)

Lynx Therapeutics Inc. (LYNX)

Northeastern University

Service agreement

To study the regulation of gene expression in Antarctic icefish using Lynx's Massively Parallel Signature Sequencing technology

Lynx will receive payments for the genomic discovery services it performs on the samples provided (4/10)

Medarex Inc. (MEDX)

Massachusetts Biologic Laboratories of the University of Massachusetts Medical School


For Medarex to use its UltiMAb technology to develop fully human antibodies to severe acute respiratory syndrome (SARS)

The parties will share equally the development costs of any antibody products as well as any future revenues (4/25)

Microfluidic Systems Inc.*

Defense Advanced Research Projects Agency


To build an airborne pathogen detection and identification system

Microfluidic Systems received the contract for $1.5M as part of a collaboration with the Lawrence Livermore National Laboratory (3/20)

Morphochem AG* (Germany)

German Research Center for Biotechnology (Germany)


To apply Morphochem's MOREsystem drug discovery engine to develop cancer therapeutics using tubulysins

Morphochem gained exclusive access to the center's research results on the natural substance class of small peptides isolated from myxobacteria; Morpho- chem will fund the research and will pay license fees if a therapeutic reaches the market (3/24)

NaPro BioTherapeutics Inc.(NPRO)

University of Texas M.D. Anderson Cancer Center

Exclusive licensing agreement

For worldwide rights to HN-1 peptide delivery technology

NaPro will provide the institution royalties and funding for further research (3/27)

Neurotech SA* (France)

INSERM, the French National Institute of Health for Medical Research (France)


To study interactions between the pigment epithelium and the neuronal retina and other vessels

INSERM will apply its high-throughput screening to identify genes expressed by the pigment retinal epithelium and implicated in retinal diseases (3/24)

Nexia Biotechnologies Inc. (Canada; TSE:NXB)

Defence R&D Canada-Suffield (Canada)


To research and test Protexia, a protein designed to protect people against the toxic effects of nerve gas and other organophosphate agents

Protexia is Nexia's recombinant version of butyrylcholinesterase (3/31)

Nexia Biotechnologies Inc. (Canada; TSE:NXB)

U.S. Army Medical Research Materiel Command

Research contract

To develop Protexia, Nexia's recombinant form of butyrylcholin-esterase

Nexia was awarded the C$3.94M (US$2.67M) research contract (4/4)

Paradigm Genetics Inc. (PDGM)

National Institute of Environmental Health Sciences

Exercised option

For an additional $8.4M for toxico-genomics studies

Data generated from the research will help in better understanding the short- and long-term exposures to chemicals (4/24)

Phase-1 Molecular Technology Inc.*

National Cancer Institute


For Phase-1 to provide toxicogenomics services to NCI

The service will provide insights into cancer treatments and the toxicity produced by those agents in comparison to the mechanism of antitumor action (5/6)

Pure Protein LLC*

National Institutes of Health

Licensing agreement

For the NIH's three hepatitis C-transfected cell lines to use in Pure-Protein's vaccine discovery project

Promising targets will be licensed to vaccine and drug designers (4/21)

Pyrosequencing AB (Sweden; SSE:PYRO)

Thomas Jefferson University

Sponsored research agreement

To analyze genes and develop applications for inflammatory bowel disease

The university recently purchased a PSQ HS 96A system, Pyrosequencing's genotyping platform, to advance clinical mol ecular genetics research, including in inflammatory bowel disease (3/31)

Repligen Corp. (RGEN)

Boston University Medical Center


To evaluate three approaches to quantifying changes in the symptoms of autism

Cure Autism Now awarded three grants to fund the development of new tools to quantify changes in the symptoms of autism in clinical trials (5/14)

Revotar Biopharmaceuticals AG* (Germany)

Department of Molecular Cardiology of the University Hospital RWTH Aachen (Germany)


For junctional adhesion molecule-1

Financial terms were not disclosed (5/5)

Targeted Genetics Corp. (TGEN)

Cystic Fibrosis Foundation Therapeutics Inc.


To advance the development of Targeted Genetics' product, tgAAVCF, to treat patients with cystic fibrosis

The focus of the collaboration is to conduct a Phase IIb trial to evaluate the efficacy of tgAAVCF in patients with mild to moderate CF (4/24)

Valent BioSciences Corp.* (Canada)

National Research Council of Canada's Plant Biotechnology Institute

Exclusive research partnership

To investigate agricultural applications of synthetic analogues of abscisic acid

Valent gains the first option to license the institute's technology for commercial development on a worldwide basis (5/6)

Vical Inc. (VICL)

Vaccine Research Center of the National Institute of Allergy and Infectious Diseases

Manufacturing contract agreement

To manufacture bulk DNA vaccines

The VRC will underwrite the capital for a 500-liter fermenter and related purification equipment in Vical's new manufacturing facility (5/12)

ViroLogic Inc. (VLGC)

International AIDS Vaccine Initiative


To develop vaccines against HIV/AIDS

ViroLogic's PhenoSense HIV antibody-neutralization assay will be used in IAVI-sponsored preclinical and clinical research studies evaluating HIV vaccine candidates (3/28)


This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange